Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-05-01

Clinical Trial Update: Vortioxetine for Binge Eating Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating vortioxetine for binge eating disorder has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vortioxetine (vortioxetine)

Snippet

Sponsor: University of Chicago | Conditions: Binge Eating Disorder | Phase 2 | Status: COMPLETED | Results posted: 2020-05-01